How AI, robotics, and precision medicine are transforming cancer care—bridging hope, technology, and humanity in the ongoing ...

Choosing between IUI and IVF? Compare success rates, costs, and suitability for your fertility journey. Get expert insights ...

Colossal, the company behind efforts to de-extinct the woolly mammoth and other long gone species announced Tuesday its ...

TSHA-102 granted Breakthrough Therapy designation by FDAFinalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month ...

NFL legend Tom Brady has stunned fans by revealing that his family's new dog, Junie, is a clone of his late pit bull mix, Lua ...

Colossal Biosciences, the world's de-extinction company, today announced its acquisition of Viagen Pets and Equine, the global leader and expert in animal cloning. Viagen provides genetic preservation ...

The grantmaking organization Open Philanthropy has awarded funding for a University of California San Diego technology ...

The MarketWatch News Department was not involved in the creation of this content.-- Third quarter revenue increased 15% year-over-year to $44.2 million -- Commercial Cell & Gene T ...

New research shows most U.S. zoo giraffes are hybrids, raising concerns about their role in real-world giraffe conservation.

The $10 billion de-extinction firm, led by Ben Lamm, has acquired Austin’s Viagen Pets and Equine to advance its species preservation mission.

South Rampart Pharma is working to develop an oral small molecule non-opioid pain treatment which has generated early positive clinical data as a therapy for acute and chronic pain, as well as ...